RU2268716C2 - Способ применения ингибиторов циклооксигеназы-2 в качестве антиангиогенных средств - Google Patents

Способ применения ингибиторов циклооксигеназы-2 в качестве антиангиогенных средств Download PDF

Info

Publication number
RU2268716C2
RU2268716C2 RU99112952/14A RU99112952A RU2268716C2 RU 2268716 C2 RU2268716 C2 RU 2268716C2 RU 99112952/14 A RU99112952/14 A RU 99112952/14A RU 99112952 A RU99112952 A RU 99112952A RU 2268716 C2 RU2268716 C2 RU 2268716C2
Authority
RU
Russia
Prior art keywords
radicals
benzenesulfonamide
pyrazol
phenyl
trifluoromethyl
Prior art date
Application number
RU99112952/14A
Other languages
English (en)
Russian (ru)
Other versions
RU99112952A (ru
Inventor
Джэйм Л. МАСФЕРРЕР (US)
Джэйм Л. МАСФЕРРЕР
Амирам РАЗ (IL)
Амирам РАЗ
Original Assignee
Джи. Ди. Сирл Энд Ко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи. Ди. Сирл Энд Ко filed Critical Джи. Ди. Сирл Энд Ко
Publication of RU99112952A publication Critical patent/RU99112952A/ru
Application granted granted Critical
Publication of RU2268716C2 publication Critical patent/RU2268716C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU99112952/14A 1996-11-19 1997-11-19 Способ применения ингибиторов циклооксигеназы-2 в качестве антиангиогенных средств RU2268716C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
US60/031,404 1996-11-19

Publications (2)

Publication Number Publication Date
RU99112952A RU99112952A (ru) 2001-05-27
RU2268716C2 true RU2268716C2 (ru) 2006-01-27

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99112952/14A RU2268716C2 (ru) 1996-11-19 1997-11-19 Способ применения ингибиторов циклооксигеназы-2 в качестве антиангиогенных средств

Country Status (19)

Country Link
EP (1) EP0941080A2 (no)
JP (1) JP2001505564A (no)
KR (1) KR20000053362A (no)
CN (1) CN1247470A (no)
AU (1) AU730211B2 (no)
BR (1) BR9713522A (no)
CA (1) CA2270469C (no)
CZ (1) CZ176899A3 (no)
ID (1) ID21979A (no)
IL (1) IL129604A (no)
NO (1) NO992309L (no)
NZ (1) NZ335853A (no)
PL (2) PL194717B1 (no)
RO (1) RO118566B1 (no)
RU (1) RU2268716C2 (no)
SK (1) SK59999A3 (no)
TR (1) TR199901703T2 (no)
UA (1) UA70294C2 (no)
WO (1) WO1998022101A2 (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2472523C2 (ru) * 2006-08-16 2013-01-20 Марлин Ньютрасьютикалз, Инк. Лечение глазных болезней
RU2684315C2 (ru) * 2011-11-01 2019-04-05 Валиркс Плк Медицинское применение

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
NZ513965A (en) * 1999-03-10 2004-04-30 G Method and composition for administering a cyclooxygenase-2 inhibitor
US6355628B1 (en) * 1999-07-29 2002-03-12 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides
DE60112742T2 (de) 2000-05-19 2006-02-02 Applied Research Systems Ars Holding N.V. Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
BR0312744A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com um inibidor selectivo da ciclooxigenase-2, à excepção do celecoxib ou valdecoxib
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406903T2 (de) * 1993-01-15 1998-04-09 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
ATE212985T1 (de) * 1993-11-30 2002-02-15 Searle & Co Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
CA2206978A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAKRABORTY I. et al. Developmental expression of the cyclo- oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol. 1996, Apr; 16(2), 107-22. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2472523C2 (ru) * 2006-08-16 2013-01-20 Марлин Ньютрасьютикалз, Инк. Лечение глазных болезней
RU2684315C2 (ru) * 2011-11-01 2019-04-05 Валиркс Плк Медицинское применение

Also Published As

Publication number Publication date
AU7298298A (en) 1998-06-10
PL194717B1 (pl) 2007-06-29
CA2270469C (en) 2007-04-10
WO1998022101A3 (en) 1998-06-25
PL333370A1 (en) 1999-12-06
BR9713522A (pt) 2000-03-21
CA2270469A1 (en) 1998-05-28
CN1247470A (zh) 2000-03-15
CZ176899A3 (cs) 1999-10-13
AU730211B2 (en) 2001-03-01
EP0941080A2 (en) 1999-09-15
NZ335853A (en) 2002-02-01
IL129604A (en) 2004-08-31
TR199901703T2 (xx) 2000-07-21
NO992309D0 (no) 1999-05-12
PL191793B1 (pl) 2006-07-31
ID21979A (id) 1999-08-19
SK59999A3 (en) 2000-01-18
UA70294C2 (en) 2004-10-15
JP2001505564A (ja) 2001-04-24
NO992309L (no) 1999-05-12
IL129604A0 (en) 2000-02-29
KR20000053362A (ko) 2000-08-25
RO118566B1 (ro) 2003-07-30
WO1998022101A2 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
US6025353A (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
RU2239429C2 (ru) Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии
US5972986A (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
RU2268716C2 (ru) Способ применения ингибиторов циклооксигеназы-2 в качестве антиангиогенных средств
WO1998016227A9 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
CA2372912C (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
IL154502A (en) Use of cyclooxygenase-2 inhibitors in the preparation of medicaments for treating angiogenesis-related disorders
NZ517374A (en) Method of using cycloozygenase-2 inhibitors to prevent a neoplasia that produces a prostaglandin

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081120